Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arnaud D Roth

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Annals of Surgical Oncology|October 3, 2007
Improved long-term outcome of surgery for advanced colorectal liver metastases: reasons and implications for management on the basis of a severity scoreAxel Andres, Pietro E Majno, Philippe Morel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2012
Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancerVlad Popovici, Eva Budinska, Sabine Tejpar, et al.
Journal of the National Cancer Institute|October 30, 2012
Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancerArnaud D Roth, Mauro Delorenzi, Sabine Tejpar, et al.
Annals of Surgical Oncology|September 10, 2014
Rectal outcomes after a liver-first treatment of patients with stage IV rectal cancerNicolas C Buchs, Frédéric Ris, Pietro E Majno, et al.
Journal of Gastroenterology and Hepatology|December 16, 2010
Value of contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography in detection and presurgical assessment of pancreatic cancer: a prospective studyNicolas C Buchs, Leo Bühler, Pascal Bucher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2002
Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancerMarkus M Borner, Daniel Dietrich, Roger Stupp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trialArnaud D Roth, Sabine Tejpar, Mauro Delorenzi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2007
Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer ResearchArnaud D Roth, Nicola Fazio, Roger Stupp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2016
BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene ExpressionDavid Barras, Edoardo Missiaglia, Pratyaksha Wirapati, et al.
The Lancet. Oncology|July 17, 2009
Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trialRoger Stupp, Michael Mayer, Roger Kann, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Annals of Surgical Oncology|October 3, 2007
Improved long-term outcome of surgery for advanced colorectal liver metastases: reasons and implications for management on the basis of a severity scoreAxel Andres, Pietro E Majno, Philippe Morel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2012
Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancerVlad Popovici, Eva Budinska, Sabine Tejpar, et al.
Journal of the National Cancer Institute|October 30, 2012
Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancerArnaud D Roth, Mauro Delorenzi, Sabine Tejpar, et al.
Annals of Surgical Oncology|September 10, 2014
Rectal outcomes after a liver-first treatment of patients with stage IV rectal cancerNicolas C Buchs, Frédéric Ris, Pietro E Majno, et al.
Journal of Gastroenterology and Hepatology|December 16, 2010
Value of contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography in detection and presurgical assessment of pancreatic cancer: a prospective studyNicolas C Buchs, Leo Bühler, Pascal Bucher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2002
Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancerMarkus M Borner, Daniel Dietrich, Roger Stupp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trialArnaud D Roth, Sabine Tejpar, Mauro Delorenzi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2007
Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer ResearchArnaud D Roth, Nicola Fazio, Roger Stupp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2016
BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene ExpressionDavid Barras, Edoardo Missiaglia, Pratyaksha Wirapati, et al.
The Lancet. Oncology|July 17, 2009
Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trialRoger Stupp, Michael Mayer, Roger Kann, et al.
Pageof 4